MA35192B1 - Derives de pyrazole - Google Patents
Derives de pyrazoleInfo
- Publication number
- MA35192B1 MA35192B1 MA36583A MA36583A MA35192B1 MA 35192 B1 MA35192 B1 MA 35192B1 MA 36583 A MA36583 A MA 36583A MA 36583 A MA36583 A MA 36583A MA 35192 B1 MA35192 B1 MA 35192B1
- Authority
- MA
- Morocco
- Prior art keywords
- group
- disorders
- halogen atom
- lower alkyl
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule dans laquelle r1 est un atome d'hydrogène ou un groupe phényle, facultativement substitué par un atome d'halogène, un groupe cn ou un groupe alcoxy inférieur ou un groupe alcoxy inférieur substitué par un atome d'halogène ; r2 est un atome d'hydrogène ou un groupe alkyle inférieur ; r3 est un atome d'hydrogène ou un groupe alkyle inférieur ou est un groupe phényle facultativement substitué par un ou plusieurs substituants, choisis parmi un atome d'halogène, un groupe cyano ou un groupe alcoxy inférieur substitué par un atome d'halogène, ou est un groupe pyridinyle, facultativement substitué par un atome d'halogène ou un groupe alkyle inférieur substitué par un atome d'halogène, ou est un groupe pyrimidinyle, facultativement substitué par un groupe alkyle inférieur substitué par un atome d'halogène, ou est un groupe pyrazinyle, facultativement substitué par un atome d'halogène, un groupe cyano ou un groupe alkyle inférieur substitué par un atome d'halogène ; r4 est un atome d'hydrogène, un groupe alkyle inférieur ou phényle ; z est une liaison, -ch2- ou -o- ; ou un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci. On a maintenant découvert que les composés répondant aux formules ia et ib possédaient une bonne affinité envers les récepteurs associés à une amine trace (taar), notamment envers taar1. Les composés peuvent être utilisés pour le traitement de la dépression, des troubles de l'anxiété, d'un trouble bipolaire, d'un trouble d'hyperactivité avec déficit de l'attention (thada), de troubles liés au stress, de troubles psychotiques tels que la schizophrénie, de maladies neurologiques telles que la maladie de parkinson, de troubles neurodégénératifs tels que la maladie d'alzheimer, de l'épilepsie, de la migraine, de l'hypertension, de la toxicomanie et de troubles métaboliques tels que des troubles de l'appétit, du diabète, de complications du diabète, de l'obésité, de la dyslipidémie, de troubles de la consommation d'énergie et de l'assimilation, de troubles et de dysfonctionnement de l'homéostasie de la température corporelle, de troubles du sommeil et du rythme circadien, et de troubles cardiovasculaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169217 | 2011-06-09 | ||
| PCT/EP2012/060627 WO2012168260A1 (fr) | 2011-06-09 | 2012-06-06 | Dérivés de pyrazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35192B1 true MA35192B1 (fr) | 2014-06-02 |
Family
ID=46298390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36583A MA35192B1 (fr) | 2011-06-09 | 2013-12-18 | Derives de pyrazole |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9073911B2 (fr) |
| EP (1) | EP2717873B1 (fr) |
| JP (1) | JP5914642B2 (fr) |
| KR (1) | KR101574905B1 (fr) |
| CN (1) | CN103596567B (fr) |
| AR (1) | AR088741A1 (fr) |
| AU (1) | AU2012266457B2 (fr) |
| BR (1) | BR112013031324B1 (fr) |
| CA (1) | CA2837255C (fr) |
| CL (1) | CL2013003484A1 (fr) |
| CO (1) | CO6801764A2 (fr) |
| CY (1) | CY1116778T1 (fr) |
| DK (1) | DK2717873T3 (fr) |
| EA (1) | EA024648B1 (fr) |
| EC (1) | ECSP13013072A (fr) |
| ES (1) | ES2546438T3 (fr) |
| HR (1) | HRP20151077T1 (fr) |
| IL (1) | IL229549B (fr) |
| MA (1) | MA35192B1 (fr) |
| MX (1) | MX347239B (fr) |
| MY (1) | MY162160A (fr) |
| PE (1) | PE20140934A1 (fr) |
| PH (1) | PH12013502315A1 (fr) |
| PL (1) | PL2717873T3 (fr) |
| PT (1) | PT2717873E (fr) |
| RS (1) | RS54183B1 (fr) |
| SG (1) | SG195156A1 (fr) |
| SI (1) | SI2717873T1 (fr) |
| TW (1) | TWI440636B (fr) |
| UA (1) | UA110525C2 (fr) |
| WO (1) | WO2012168260A1 (fr) |
| ZA (1) | ZA201308939B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| RU2621050C2 (ru) * | 2012-01-12 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars) |
| NO2895477T3 (fr) * | 2012-09-14 | 2018-03-31 | ||
| US9580407B2 (en) * | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| WO2015165085A1 (fr) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Dérivés de morpholine-pyridine |
| JP6814814B2 (ja) | 2016-03-17 | 2021-01-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体 |
| CN118271233A (zh) | 2017-04-24 | 2024-07-02 | 特沙诺有限公司 | 尼拉帕利的制造方法 |
| CN112457255B (zh) * | 2017-11-08 | 2022-08-19 | 北京嘉林药业股份有限公司 | 化合物及其治疗癌症的用途 |
| CN112585128B (zh) * | 2018-06-18 | 2023-02-21 | 詹森药业有限公司 | 作为malt1抑制剂的吡唑衍生物 |
| KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
| WO2020064792A1 (fr) | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Composés hétérocyclyles pour le traitement d'une maladie auto-immune |
| WO2020175957A1 (fr) * | 2019-02-28 | 2020-09-03 | 주식회사 마더스제약 | Composés dérivés d'amide de pirazole et leur utilisation |
| EP3983386A4 (fr) * | 2019-05-14 | 2023-01-11 | Metabomed Ltd | Inhibiteurs d'acss2 et leurs procédés d'utilisation |
| CA3146830A1 (fr) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Procede de preparation de derives pyrazoles substitues |
| US20240400577A1 (en) * | 2021-07-08 | 2024-12-05 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
| WO2023183444A1 (fr) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulateurs de protéines kinases |
| AU2023323858A1 (en) * | 2022-08-12 | 2024-11-21 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |
| KR20250176791A (ko) | 2024-06-13 | 2025-12-22 | 인천대학교 산학협력단 | 피라졸 유도체를 유효성분으로 포함하는 항노화 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) * | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) * | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| PT1036065E (pt) | 1997-12-04 | 2004-09-30 | Allergan Inc | Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos |
| KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ1 리간드로서의 2-아미노옥사졸린 |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9029370B2 (en) | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
| CN102899314A (zh) | 2011-07-29 | 2013-01-30 | 江汉大学 | 一种批量基因克隆的方法 |
-
2012
- 2012-06-01 US US13/485,969 patent/US9073911B2/en active Active
- 2012-06-06 ES ES12727632.7T patent/ES2546438T3/es active Active
- 2012-06-06 KR KR1020147000462A patent/KR101574905B1/ko not_active Expired - Fee Related
- 2012-06-06 CA CA2837255A patent/CA2837255C/fr active Active
- 2012-06-06 CN CN201280027873.0A patent/CN103596567B/zh not_active Expired - Fee Related
- 2012-06-06 SG SG2013087234A patent/SG195156A1/en unknown
- 2012-06-06 WO PCT/EP2012/060627 patent/WO2012168260A1/fr not_active Ceased
- 2012-06-06 JP JP2014514042A patent/JP5914642B2/ja not_active Expired - Fee Related
- 2012-06-06 RS RS20150549A patent/RS54183B1/sr unknown
- 2012-06-06 TW TW101120350A patent/TWI440636B/zh not_active IP Right Cessation
- 2012-06-06 PH PH1/2013/502315A patent/PH12013502315A1/en unknown
- 2012-06-06 PT PT127276327T patent/PT2717873E/pt unknown
- 2012-06-06 HR HRP20151077TT patent/HRP20151077T1/hr unknown
- 2012-06-06 UA UAA201400123A patent/UA110525C2/ru unknown
- 2012-06-06 EP EP12727632.7A patent/EP2717873B1/fr active Active
- 2012-06-06 EA EA201391787A patent/EA024648B1/ru not_active IP Right Cessation
- 2012-06-06 PE PE2013002748A patent/PE20140934A1/es active IP Right Grant
- 2012-06-06 MX MX2013013853A patent/MX347239B/es active IP Right Grant
- 2012-06-06 BR BR112013031324-2A patent/BR112013031324B1/pt not_active IP Right Cessation
- 2012-06-06 MY MYPI2013004400A patent/MY162160A/en unknown
- 2012-06-06 PL PL12727632T patent/PL2717873T3/pl unknown
- 2012-06-06 AU AU2012266457A patent/AU2012266457B2/en not_active Ceased
- 2012-06-06 DK DK12727632.7T patent/DK2717873T3/en active
- 2012-06-06 SI SI201230279T patent/SI2717873T1/sl unknown
- 2012-06-07 AR ARP120102009A patent/AR088741A1/es unknown
-
2013
- 2013-10-31 CO CO13258855A patent/CO6801764A2/es active IP Right Grant
- 2013-11-21 IL IL229549A patent/IL229549B/en active IP Right Grant
- 2013-11-27 ZA ZA2013/08939A patent/ZA201308939B/en unknown
- 2013-12-05 CL CL2013003484A patent/CL2013003484A1/es unknown
- 2013-12-09 EC ECSP13013072 patent/ECSP13013072A/es unknown
- 2013-12-18 MA MA36583A patent/MA35192B1/fr unknown
-
2015
- 2015-10-06 CY CY20151100893T patent/CY1116778T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35192B1 (fr) | Derives de pyrazole | |
| MA35194B1 (fr) | Derives de benzamide substitues | |
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| MA33855B1 (fr) | Dérivés de benzamide substitués | |
| MA32486B1 (fr) | Derives de 4,5- dihydrooxazol-2-yle | |
| MA31165B1 (fr) | Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc | |
| CN85108623A (zh) | 制备具有药用活性的杂环酰胺之新方法 | |
| CN1124960A (zh) | 作为5-ht/a和/或5-ht2配体的吲哚衍生物 | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| CN101032483A (zh) | 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用 | |
| MX2009013742A (es) | 2-imidazolinas. | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| JP6950534B2 (ja) | テトラヒドロナフタレン誘導体 | |
| MX361761B (es) | Derivados de triazol carboxamida. | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| MA37944A1 (fr) | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson | |
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| MX2009013745A (es) | 4-imidazolinas y su uso como antidepresivos. | |
| CN1288153C (zh) | 2－氨基－4－吡啶基甲基－二氢噻唑衍生物作为诱导型no－合酶抑制剂的用途 | |
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| CN1956962A (zh) | 四氢异喹啉磺酰胺衍生物，其制备方法及其在治疗中的应用 | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. |